Effects of Prebiotics on GLP-1 in Type 2 Diabetes
Primary Purpose
Diabetes Type 2
Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Prebiotic fibers: oligofructose and inulin
Maltodextrin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Type 2
Eligibility Criteria
Inclusion Criteria:
- diabetes type 2
- BMI 18,5 - 40
- Not medicated with insulin, GLP-1 analogues or DPP4 inhibitors
- Moderate intake of alcohol
- Not excessive exercise
- Less than 3 kg weight change the last two months
- Intake of less than 30 g dietary fiber per day
Exclusion Criteria:
- IBD
- IBS
- Coeliac disease
- Have used antibiotics within the last two months
- Have used supplements with prebiotics or probiotics the last two months
- Pregnancy
Sites / Locations
- Oslo University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Arm A
Arm B
Arm Description
Prebiotic fibers: Oligofructose and inulin
Maltodextrin
Outcomes
Primary Outcome Measures
Changes in plasma GLP-1 in response to standardized test meal before and after six weeks of ingestion of prebiotic fibers or placebo
The changes in GLP-1 response to either prebiotic fibers or placebo will be compared in a cross-over manner where the participants are their own controls. In between the intervention periods there will be a wash-out period of 4 weeks.
Secondary Outcome Measures
Full Information
NCT ID
NCT02569684
First Posted
September 29, 2015
Last Updated
September 15, 2020
Sponsor
Oslo University Hospital
Collaborators
Norwegian Diabetes Association, Norwegian Extra Foundation for Health and Rehabilitation
1. Study Identification
Unique Protocol Identification Number
NCT02569684
Brief Title
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
Official Title
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
October 2015 (Actual)
Primary Completion Date
January 2018 (Actual)
Study Completion Date
December 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
Collaborators
Norwegian Diabetes Association, Norwegian Extra Foundation for Health and Rehabilitation
4. Oversight
5. Study Description
Brief Summary
The aim of the study is to compare the effects of prebiotics versus placebo on blood concentrations of glucagon-like peptide-1 in subjects with diabetes type 2.
Detailed Description
We looked at 6 weeks supplementation with a prebiotic fibre mix of inulin and FOS. Cross over design compared to maltodextrin as placebo. Additional outcome measures: blood glucose, insulin, GLP-2, ghrelin, PYY and leptin after a standardized mixed meal test. Also measured changes in microbiota composition and SCFA in feces before and after intervention/placebo periods, and subjective measures of appetite.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
37 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm A
Arm Type
Active Comparator
Arm Description
Prebiotic fibers: Oligofructose and inulin
Arm Title
Arm B
Arm Type
Placebo Comparator
Arm Description
Maltodextrin
Intervention Type
Dietary Supplement
Intervention Name(s)
Prebiotic fibers: oligofructose and inulin
Intervention Type
Dietary Supplement
Intervention Name(s)
Maltodextrin
Primary Outcome Measure Information:
Title
Changes in plasma GLP-1 in response to standardized test meal before and after six weeks of ingestion of prebiotic fibers or placebo
Description
The changes in GLP-1 response to either prebiotic fibers or placebo will be compared in a cross-over manner where the participants are their own controls. In between the intervention periods there will be a wash-out period of 4 weeks.
Time Frame
six weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diabetes type 2
BMI 18,5 - 40
Not medicated with insulin, GLP-1 analogues or DPP4 inhibitors
Moderate intake of alcohol
Not excessive exercise
Less than 3 kg weight change the last two months
Intake of less than 30 g dietary fiber per day
Exclusion Criteria:
IBD
IBS
Coeliac disease
Have used antibiotics within the last two months
Have used supplements with prebiotics or probiotics the last two months
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne-Marie Aas, PhD
Organizational Affiliation
Oslo University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oslo University Hospital
City
Oslo
ZIP/Postal Code
0424
Country
Norway
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34297363
Citation
Birkeland E, Gharagozlian S, Gulseth HL, Birkeland KI, Hartmann B, Holst JJ, Holst R, Aas AM. Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial. Diabet Med. 2021 Oct;38(10):e14657. doi: 10.1111/dme.14657. Epub 2021 Aug 7.
Results Reference
derived
PubMed Identifier
32440730
Citation
Birkeland E, Gharagozlian S, Birkeland KI, Valeur J, Mage I, Rud I, Aas AM. Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial. Eur J Nutr. 2020 Oct;59(7):3325-3338. doi: 10.1007/s00394-020-02282-5. Epub 2020 May 21. Erratum In: Eur J Nutr. 2020 Jul 6;:
Results Reference
derived
Learn more about this trial
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
We'll reach out to this number within 24 hrs